Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jasper Dingemanse

Showing results (61-70 of 246) with videos related to

Pageof 25
Sort By:
Clinical Pharmacokinetics|September 18, 2016
Impact of Demographics, Organ Impairment, Disease, Formulation, and Food on the Pharmacokinetics of the Selective S1P<sub>1</sub> Receptor Modulator Ponesimod Based on 13 Clinical StudiesDominik Lott, Thorsten Lehr, Jasper Dingemanse, et al.
European Journal of Clinical Pharmacology|November 26, 2016
Absolute oral bioavailability of selexipag, a novel oral prostacyclin IP receptor agonistPriska Kaufmann, Noémie Hurst, Béatrice Astruc, et al.
Journal of Sleep Research|April 22, 2023
The orexin story and orexin receptor antagonists for the treatment of insomniaClemens Muehlan, Catherine Roch, Cedric Vaillant, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|January 28, 2012
A randomized placebo-controlled trial of miglustat in cystic fibrosis based on nasal potential differenceAnissa Leonard, Patrick Lebecque, Jasper Dingemanse, et al.
Clinical Therapeutics|March 19, 2013
Comparative pharmacokinetic, pharmacodynamic, safety, and tolerability profiles of 3 different formulations of epoprostenol sodium for injection in healthy menLaurent B Nicolas, Marcelo M Gutierrez, Jasper Dingemanse
Pharmacology|October 4, 2014
Multiple-dose up-titration study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of selexipag, an orally available selective prostacyclin receptor agonist, in healthy subjectsShirin Bruderer, Noémie Hurst, Priska Kaufmann, et al.
Journal of Clinical Pharmacology|February 9, 2020
Impact of the Selective Orexin-1 Receptor Antagonist ACT-539313 on the Pharmacokinetics of the CYP3A Probe Drug Midazolam in Healthy Male SubjectsBenjamin Berger, Priska Kaufmann, Annelize Koch, et al.
Clinical and Translational Science|June 14, 2021
Pharmacokinetics of daridorexant, a dual orexin receptor antagonist, are not affected by renal impairmentBenjamin Berger, Clemens Muehlan, Gernot Klein, et al.
Pharmacology|November 18, 2014
Effects of ethnicity and sex on the pharmacokinetics and pharmacodynamics of the selective sphingosine-1-phosphate receptor 1 modulator ponesimod: a clinical study in Japanese and Caucasian subjectsMaribel Reyes, Matthias Hoch, Patrick Brossard, et al.
European Journal of Clinical Pharmacology|November 28, 2007
Mutual pharmacokinetic interactions between steady-state bosentan and sildenafilGary Burgess, Hans Hoogkamer, Lorraine Collings, et al.
Pageof 25

Showing results (61-70 of 246) with videos related to

Sort By:
Pageof 25
Clinical Pharmacokinetics|September 18, 2016
Impact of Demographics, Organ Impairment, Disease, Formulation, and Food on the Pharmacokinetics of the Selective S1P<sub>1</sub> Receptor Modulator Ponesimod Based on 13 Clinical StudiesDominik Lott, Thorsten Lehr, Jasper Dingemanse, et al.
European Journal of Clinical Pharmacology|November 26, 2016
Absolute oral bioavailability of selexipag, a novel oral prostacyclin IP receptor agonistPriska Kaufmann, Noémie Hurst, Béatrice Astruc, et al.
Journal of Sleep Research|April 22, 2023
The orexin story and orexin receptor antagonists for the treatment of insomniaClemens Muehlan, Catherine Roch, Cedric Vaillant, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|January 28, 2012
A randomized placebo-controlled trial of miglustat in cystic fibrosis based on nasal potential differenceAnissa Leonard, Patrick Lebecque, Jasper Dingemanse, et al.
Clinical Therapeutics|March 19, 2013
Comparative pharmacokinetic, pharmacodynamic, safety, and tolerability profiles of 3 different formulations of epoprostenol sodium for injection in healthy menLaurent B Nicolas, Marcelo M Gutierrez, Jasper Dingemanse
Pharmacology|October 4, 2014
Multiple-dose up-titration study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of selexipag, an orally available selective prostacyclin receptor agonist, in healthy subjectsShirin Bruderer, Noémie Hurst, Priska Kaufmann, et al.
Journal of Clinical Pharmacology|February 9, 2020
Impact of the Selective Orexin-1 Receptor Antagonist ACT-539313 on the Pharmacokinetics of the CYP3A Probe Drug Midazolam in Healthy Male SubjectsBenjamin Berger, Priska Kaufmann, Annelize Koch, et al.
Clinical and Translational Science|June 14, 2021
Pharmacokinetics of daridorexant, a dual orexin receptor antagonist, are not affected by renal impairmentBenjamin Berger, Clemens Muehlan, Gernot Klein, et al.
Pharmacology|November 18, 2014
Effects of ethnicity and sex on the pharmacokinetics and pharmacodynamics of the selective sphingosine-1-phosphate receptor 1 modulator ponesimod: a clinical study in Japanese and Caucasian subjectsMaribel Reyes, Matthias Hoch, Patrick Brossard, et al.
European Journal of Clinical Pharmacology|November 28, 2007
Mutual pharmacokinetic interactions between steady-state bosentan and sildenafilGary Burgess, Hans Hoogkamer, Lorraine Collings, et al.
Pageof 25